Fresh analysis suggests that patients who stop using popular GLP-1 drugs like Wegovy and Mounjaro tend to recover lost weight far faster than those who end conventional diet and exercise programs.
Findings released in a major medical journal points out that while overweight people often shed substantial amounts of their total mass while on the medication, the mass comes back at an average rate of 0.8 kg per month upon discontinuation.
"Individuals buying these medications need to be cognizant of the risk of fast weight regain when the treatment is stopped," warns expert Dr. Susan Jebb.
This pace of recovery implies a reversion to original mass within about one and a half years.
Weighing Approaches
The analysis, which reviewed 37 of trials involving over 9,000 of participants, contrasted the results of the injectable medications with other pills.
The team note that people who shed pounds through dieting typically have a less rapid weight regain—approximately 0.1 kg a month—once they finish.
Explaining the Quick Regain
Doctors propose the mode of action of the jabs accounts for the accelerated regain.
These medications mimic a body's own chemical called glucagon-like peptide-1, which helps regulate appetite.
"Artificially providing the hormone concentrations several times higher than normal might result in the system to produce less of its own natural GLP-1, and may also reduce responsiveness to its effects," noted Dr. Adam Collins, a dietetics specialist.
"Discontinuation of this medication results in appetite is unsuppressed, making overeating a significant risk."
An Ongoing Disease?
Health authorities advise the jabs for people with obesity-related medical conditions, accompanied by prescribed lifestyle changes.
Many experts argue that, given the likelihood of weight regain, the treatment should be considered long-term.
This perspective is supported by drug manufacturers, who state that the findings "underscore the persistent character of obesity," similar to managing conditions like diabetes.
User Accounts
Individuals who have discontinued the medication describe a powerful return of appetite.
"It was like a trigger flipping and you become extremely hungry," described a patient.
This difficulty is exacerbated if patients have not established lasting lifestyle or habit modifications during treatment.
Widespread Adoption
Survey data suggest that millions of people in the UK have used weight-loss jabs in the last 12 months, with interest continuing to grow.
- Use is higher among women compared to men.
- The middle-aged age group shows the highest level of interest.
- Many access the drugs through private prescriptions rather than the NHS.
Ultimately, clinicians emphasize that while these medications are potent agents for shedding pounds, they are not a standalone solution and long-term success hinges on integrated behavioural support.
